What Is Dihexa? Mechanism, Uses, Risks, and FDA Status
What Is Dihexa?
Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is a synthetic peptide analog of angiotensin IV developed by researchers at Washington State University, led by Dr. Joseph Harding and Dr. John Wright. It was designed to be a stable, orally active analog of the endogenous brain peptide angiotensin IV, which plays a role in memory and cognitive function through the hepatocyte growth factor (HGF)/c-Met receptor system. Dihexa gained significant attention in the nootropic community after research suggested it was approximately seven orders of magnitude (10 million times) more potent than brain-derived neurotrophic factor (BDNF) at promoting synaptic connections in vitro.
How Does Dihexa Work?
Dihexa's mechanism centers on the HGF/c-Met signaling pathway rather than the classical renin-angiotensin system:
- HGF/c-Met activation — Dihexa acts as a potent agonist of the hepatocyte growth factor receptor (c-Met), which promotes neuronal survival, dendritic branching, and synaptogenesis (McCoy et al., J Pharmacol Exp Ther, 2013)
- Synaptogenesis — Research demonstrates Dihexa promotes the formation of new synaptic connections between neurons at extraordinarily low concentrations (picomolar range)
- Dendritic spine formation — The compound stimulates growth of dendritic spines, the structural basis of synaptic plasticity and memory
- Blood-brain barrier penetration — Unlike angiotensin IV, Dihexa was designed to cross the blood-brain barrier and resist enzymatic degradation
- Oral bioavailability — The hexanoic acid modifications provide stability against peptidases, enabling oral administration
The extreme potency of Dihexa in promoting synaptic connectivity (active at picomolar concentrations) distinguishes it from other nootropic compounds and suggests a highly efficient receptor-mediated mechanism.
What Is Dihexa Used For?
Based on published research (exclusively preclinical), Dihexa has been investigated for:
- Cognitive enhancement — Dihexa restored cognitive function in aged rats and in scopolamine-induced amnesia models (McCoy et al., 2013)
- Alzheimer's disease — Research suggests potential for restoring synaptic connectivity lost in neurodegenerative conditions
- Traumatic brain injury — Preliminary investigation into promoting neural repair following brain trauma
- Age-related cognitive decline — Animal studies demonstrate reversal of age-associated memory deficits
- Neurodegenerative disease research — Used as a tool compound to study HGF/c-Met signaling in neuronal survival and plasticity
What Are the Risks and Side Effects?
- No human clinical data — Dihexa has never been tested in human clinical trials; all evidence comes from in vitro and animal studies
- Unknown safety profile — Toxicology, pharmacokinetics, and adverse effects in humans are completely uncharacterized
- HGF/c-Met and cancer — The HGF/c-Met pathway is frequently dysregulated in cancer; chronic activation raises significant theoretical concerns about tumor promotion or progression (Organ & Bhatt, Clin Cancer Res, 2011)
- Potency concerns — The extreme potency of Dihexa (active at picomolar concentrations) means dosing errors could have outsized effects
- No established dosing — Human-equivalent doses have not been determined through proper allometric scaling and safety studies
- Cardiovascular unknowns — As an angiotensin system analog, potential cardiovascular effects cannot be ruled out
- Quality and purity — Available only as a research chemical; no pharmaceutical-grade manufacturing standards apply
- Irreversible neural changes — Promoting synaptogenesis is not inherently beneficial; aberrant connectivity could theoretically contribute to seizure susceptibility or other neurological issues
FDA Status
Dihexa is classified as unregulated — it has no FDA approval, no IND application, and no clinical trials registered. It is available exclusively as a research chemical and is not available through legitimate compounding pharmacies for human use. It has not been nominated for PCAC review. The compound remains in the earliest stages of preclinical development. For the latest regulatory updates, visit our FDA tracker.
Key Studies and Evidence Base
| Study | Finding | |-------|---------| | McCoy et al., 2013 (J Pharmacol Exp Ther) | Dihexa restored cognitive function in aged and scopolamine-treated rats; promoted synaptogenesis at picomolar concentrations | | Benoist et al., 2014 | Dihexa augmented synaptic connectivity and dendritic spine density in hippocampal neurons | | Wright & Harding, 2011 (Prog Neurobiol) | Review of angiotensin IV/AT4 receptor system in cognition; foundation for Dihexa development | | Harding et al., 2018 | Patent filing describing Dihexa analogs for neurodegenerative disease applications |
The Bottom Line
Dihexa is one of the most potent pro-cognitive compounds identified in preclinical research, with remarkable ability to promote synaptic connectivity at extremely low concentrations. However, it carries significant unknowns: no human safety data exists, the HGF/c-Met pathway has well-documented roles in cancer biology, and the long-term consequences of artificially promoting synaptogenesis are unclear. Unlike many peptides discussed on this site, Dihexa has no compounding pathway, no clinical trials, and no regulatory framework for human use. It should be considered a research compound only, and anyone encountering it should exercise extreme caution given the complete absence of human safety data.
This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy. TruPeptide does not sell peptides or facilitate purchases.